Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
PARSIPPANY, N.J., Jan. 24, 2013 /PRNewswire/ -- Watson
Pharmaceuticals, Inc. today announced that the company has adopted
Actavis, Inc. (NYSE: ACT) as its new global name and will today
begin trading under a new symbol — ACT — on the New York Stock
Exchange.
The company first announced its intention to change its name
last year, following its acquisition of the Actavis Group.
The combination created the world's third largest generic
pharmaceutical company, with anticipated pro forma combined 2012
revenues in excess of $8 billion.
Actavis has initiated a multi-year rebranding campaign that will
guide the transition of its facilities, operations and commercial
presence around the world to the new company name and logo.
The company has launched a new global web site and will today ring
The Closing Bell on the New York Stock Exchange.
"Today marks an historic day for Actavis and a milestone in our
evolution into a global pharmaceutical leader," said Paul Bisaro, President and CEO of Actavis.
"While we have been operating as one company since last year, today
we unite all of our 17,000 employees under a single name,
trademarked and protected around the world."
"With operations in more than 60 countries and a top 10 position
in over 33 markets, Actavis is a dynamic global player that is
recognized worldwide as a leader in providing high-quality
pharmaceuticals," Bisaro said. "As we move forward into this
exciting future for our company, we are committed to continuing the
rapid and seamless execution of our integration planning efforts to
provide maximum value to all of our customers and shareholders
around the world."
Actavis has also today adopted a distinctive redesign of the
company name, designed by the leading global identity firm
Lippincott.
The new icon in the logo speaks to the company's fast-evolving
business, as well as its dynamic culture. A close look
reveals a "W" shape emerging from a shaded "A," a subtle historical
reference to the Watson heritage and acquisition of Actavis.
The color stands out in the universe of pharmaceutical industry
competitors and reflects growth — a fundamental foundation for
Actavis and its future — and a commitment to be an environmentally
responsible company.
The result is a new, powerful and accessible visualization that
celebrates Actavis' emergence as a global pharmaceutical leader,
and visually defines its focus on growth and success in the
future.
About Actavis
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty
pharmaceutical company focused on developing, manufacturing and
distributing generic, brand and biosimilar products. The
Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international
headquarters in Zug, Switzerland.
Actavis is the world's third-largest generics prescription drug
manufacturer. Operating as Actavis Pharma, the Company
develops, manufactures and markets generic, branded generic, legacy
brands and Over-the-Counter (OTC) products in more than 60
countries. The Company is ranked in the top 3 in 12 global
markets, the top 5 in 16 global markets, and in the top 10 in 33
global markets. Actavis Pharma also develops and
out-licenses generic pharmaceutical products outside the U.S.
through its Medis third-party business, the world's largest generic
pharmaceutical out-licensing business. Medis has more than 300
customers globally, and offers a broad portfolio of more than 200
products.
Actavis Specialty Brands is the Company's global branded
specialty pharmaceutical business, which develops and markets a
portfolio of approximately 40 products principally in the United States and Canada that are focused in the Urology and
Women's Health therapeutic categories. Actavis Specialty
Brands is committed to developing and marketing biosimilars
products in Women's Health, Oncology and other therapeutic
categories, and currently has a portfolio of 5 biosimilar products
in development.
Actavis Global Operations has more than 30 manufacturing and
distribution facilities around the world, with a capacity of
approximately 40 billion units annually. Actavis Global
Operations also includes Anda, Inc., the fourth-largest U.S.
generic pharmaceutical product distributor in the United States.
For press release and other company information, visit Actavis'
Web site at http://www.actavis.com.
Forward-Looking Statement
Statements contained in this press release that refer to
Actavis' estimated or anticipated future results or other
non-historical facts are forward-looking statements that reflect
Actavis' current perspective of existing trends and information as
of the date of this release. For instance, any statements in this
press release concerning prospects related to Actavis' strategic
initiatives, product introductions and anticipated financial
performance are forward-looking statements. It is important to note
that Actavis' goals and expectations are not predictions of actual
performance. Actavis' performance, at times, will differ from its
goals and expectations. Actual results may differ materially from
Actavis' current expectations depending upon a number of factors
affecting Actavis' business. These factors include, among others,
the inherent uncertainty associated with financial projections;
successful integration of the legacy Actavis acquisition and the
ability to recognize the anticipated synergies and benefits of the
legacy Actavis acquisition; the difficulty of predicting the timing
and outcome of pending or future litigation and government
investigations and risks that an adverse outcome in such litigation
or investigations could render Actavis liable for substantial
damages or penalties; risks that resolution of patent infringement
litigation through settlement could result in investigations or
actions by private parties or government authorities or agencies;
the impact of competitive products and pricing; risks related to
fluctuations in foreign currency exchange rates; periodic
dependence on a small number of products for a material source of
net revenue or income; variability of trade buying patterns;
changes in generally accepted accounting principles; risks that the
carrying values of assets may be negatively impacted by future
events and circumstances; the timing and success of product
launches; the difficulty of predicting the timing or outcome of
product development efforts and regulatory agency approvals or
actions, if any; risks and uncertainties normally incident to the
pharmaceutical industry, including product liability claims and the
availability of product liability insurance on reasonable terms;
market acceptance of and continued demand for Actavis' products;
difficulties or delays in manufacturing; the availability and
pricing of third party sourced products and materials; successful
compliance with governmental regulations applicable to Actavis'
facilities, products and/or businesses; changes in the laws and
regulations, including Medicare, Medicaid, and similar laws in
foreign countries affecting, among other things, pricing and
reimbursement of pharmaceutical products and the settlement of
patent litigation; and such other risks and uncertainties detailed
in Actavis' periodic public filings with the Securities and
Exchange Commission, including but not limited to Actavis' Annual
Report on Form 10-K for the year ended December 31, 2011 and Actavis' Quarterly Report
on Form 10-Q for the period September 30,
2012 (such periodic public filings having been filed under
the "Watson Pharmaceuticals, Inc." name). Except as expressly
required by law, Actavis disclaims any intent or obligation to
update these forward-looking statements.
CONTACTS:
|
Investors:
|
|
Lisa
DeFrancesco
|
|
(862)
261-7152
|
|
|
|
Media:
|
|
Charlie
Mayr
|
|
(862)
261-8030
|
(Logo: http://photos.prnewswire.com/prnh/20130124/NY47381LOGO
)
SOURCE Watson Pharmaceuticals, Inc.; Actavis, Inc.